Thomas E. Hughes

7.7k total citations · 2 hit papers
51 papers, 3.6k citations indexed

About

Thomas E. Hughes is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Hematology. According to data from OpenAlex, Thomas E. Hughes has authored 51 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Oncology and 13 papers in Hematology. Recurrent topics in Thomas E. Hughes's work include Diabetes Treatment and Management (16 papers), Peptidase Inhibition and Analysis (12 papers) and Hematopoietic Stem Cell Transplantation (10 papers). Thomas E. Hughes is often cited by papers focused on Diabetes Treatment and Management (16 papers), Peptidase Inhibition and Analysis (12 papers) and Hematopoietic Stem Cell Transplantation (10 papers). Thomas E. Hughes collaborates with scholars based in United States, Sweden and Australia. Thomas E. Hughes's co-authors include Jens J. Holst, Peter Novick, Fern P. Finger, Mary E. Russell, Sten Madsbad, Linda Hilsted, Mette Brimnes Damholt, B Michelsen, M. Toft-Nielsen and Carolyn F. Deacon and has published in prestigious journals such as Cell, Neuron and Journal of Clinical Oncology.

In The Last Decade

Thomas E. Hughes

50 papers receiving 3.5k citations

Hit Papers

Determinants of the Impaired Secretion of Glucagon-Like P... 2001 2026 2009 2017 2001 2003 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients
    2001 702 citations Thomas E. Hughes et al. profile →
  2. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:  A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties
    2003 519 citations Bryan F. Burkey, Mary E. Russell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas E. Hughes United States 26 1.8k 1.3k 1.0k 812 800 51 3.6k
Pomila Singh United States 37 564 0.3× 1.6k 1.2× 1.0k 1.0× 1.0k 1.3× 637 0.8× 125 3.7k
Hueng-Sik Choi South Korea 31 697 0.4× 2.5k 1.9× 949 0.9× 886 1.1× 446 0.6× 67 4.4k
Hans‐Ulrich Demuth Germany 31 1.5k 0.9× 1.4k 1.0× 2.0k 1.9× 609 0.8× 1.5k 1.8× 75 3.4k
John M. Kokontis United States 34 1.2k 0.7× 2.6k 1.9× 1.1k 1.1× 636 0.8× 340 0.4× 52 4.7k
Jeffrey N. Miner United States 35 972 0.6× 2.1k 1.5× 603 0.6× 535 0.7× 263 0.3× 71 4.7k
Shutsung Liao United States 30 1.4k 0.8× 1.7k 1.3× 449 0.4× 352 0.4× 212 0.3× 60 3.8k
S Andersson United States 13 905 0.5× 1.4k 1.0× 443 0.4× 459 0.6× 175 0.2× 15 2.7k
M. Page Haynes United States 18 694 0.4× 1.4k 1.0× 348 0.3× 454 0.6× 168 0.2× 20 3.0k
Maryvonne Rosseneu Belgium 32 1.0k 0.6× 2.3k 1.7× 343 0.3× 1.2k 1.5× 120 0.1× 88 3.9k
Jinny S. Wong United States 27 789 0.4× 2.0k 1.5× 296 0.3× 1.2k 1.4× 149 0.2× 31 4.1k

Countries citing papers authored by Thomas E. Hughes

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Hughes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Hughes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Hughes more than expected).

Fields of papers citing papers by Thomas E. Hughes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Hughes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Hughes. The network helps show where Thomas E. Hughes may publish in the future.

Co-authorship network of co-authors of Thomas E. Hughes

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Hughes. A scholar is included among the top collaborators of Thomas E. Hughes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Hughes. Thomas E. Hughes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dimitrova, Dimana, Seth M. Steinberg, Jennifer Cuellar‐Rodríguez, et al.. (2021). Phase I Study De-Intensifying Exposure of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. Transplantation and Cellular Therapy. 27(3). S9–S11. 1 indexed citations
3.
Hughes, Thomas E., et al.. (2020). A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. Bone Marrow Transplantation. 55(6). 1085–1092. 3 indexed citations
4.
Burkey, Bryan F., et al.. (2018). Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061. Journal of Pharmacology and Experimental Therapeutics. 365(2). 301–313. 31 indexed citations
5.
Parta, Mark, Nirali N. Shah, Kristin Baird, et al.. (2018). Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. Biology of Blood and Marrow Transplantation. 24(6). 1250–1259. 55 indexed citations
6.
Herndon, Thomas M., Nakhle S. Saba, Janet Valdez, et al.. (2017). Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia. 31(6). 1340–1347. 88 indexed citations
7.
Grossman, Jennifer, Jennifer Cuellar‐Rodríguez, Juan Gea‐Banacloche, et al.. (2014). Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency. Biology of Blood and Marrow Transplantation. 20(12). 1940–1948. 64 indexed citations
8.
Duttaroy, Alokesh, et al.. (2010). The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. European Journal of Pharmacology. 650(2-3). 703–707. 55 indexed citations
9.
10.
Dorfman, Suzanne E., John Gounarides, Xue Li, et al.. (2009). Metabolic Implications of Dietary Trans‐fatty Acids. Obesity. 17(6). 1200–1207. 80 indexed citations
11.
Hughes, Thomas E.. (2009). Emerging therapies for metabolic diseases—the focus is on diabetes and obesity. Current Opinion in Chemical Biology. 13(3). 332–337. 22 indexed citations
12.
Gromada, Jesper & Thomas E. Hughes. (2006). Ringing the dinner bell for insulin: Muscarinic M3 receptor activity in the control of pancreatic β cell function. Cell Metabolism. 3(6). 390–392. 12 indexed citations
13.
Burkey, B F, M Kellis, Leonardo Bolognese, et al.. (2005). Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats. Journal of Pharmacology and Experimental Therapeutics. 315(2). 688–695. 95 indexed citations
14.
Åhrén, Bo, Maria Sörhede Winzell, Bryan F. Burkey, & Thomas E. Hughes. (2005). Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. European Journal of Pharmacology. 521(1-3). 164–168. 24 indexed citations
15.
Mitani, Hironobu, Misato Takimoto, Thomas E. Hughes, & Masaaki Kimura. (2002). Dipeptidyl Peptidase IV Inhibition Improves Impaired Glucose Tolerance in High-Fat Diet-Fed Rats: Study Using a Fischer 344 Rat Substrain Deficient in Its Enzyme Activity. The Japanese Journal of Pharmacology. 88(4). 442–450. 54 indexed citations
16.
Finger, Fern P., Thomas E. Hughes, & Peter Novick. (1998). Sec3p Is a Spatial Landmark for Polarized Secretion in Budding Yeast. Cell. 92(4). 559–571. 312 indexed citations
17.
Handley, Dean A. & Thomas E. Hughes. (1997). PHARMACOLOGICAL APPROACHES AND STRATEGIES FOR THERAPEUTIC MODULATION OF FIBRINOGEN. Thrombosis Research. 87(1). 1–36. 17 indexed citations
18.
Marshall, John, Raymond Molloy, Guy W. J. Moss, James R. Howe, & Thomas E. Hughes. (1995). The jellyfish green fluorescent protein: A new tool for studying ion channel expression and function. Neuron. 14(2). 211–215. 215 indexed citations
19.
20.
Hughes, Thomas E., et al.. (1991). Altretamine. DICP. 25(2). 146–152. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pomila Singh Breakdown of academic impact, for papers by Hueng-Sik Choi Breakdown of academic impact, for papers by Hans‐Ulrich Demuth Breakdown of academic impact, for papers by John M. Kokontis Breakdown of academic impact, for papers by Jeffrey N. Miner Breakdown of academic impact, for papers by Shutsung Liao Breakdown of academic impact, for papers by S Andersson Breakdown of academic impact, for papers by M. Page Haynes Breakdown of academic impact, for papers by Maryvonne Rosseneu Breakdown of academic impact, for papers by Jinny S. Wong
Rankless by CCL
2026